Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ephedrine in Congenital Myasthenia
NCT00541216Phase 2Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in congenital myasthenic syndrome (CMS) comparing Ephedrine Sequence with Placebo Sequence (2 arms). Primary endpoint: Strength and fatiguability at 5 weeks. Status: unknown.
02
Drugs
ephedrine
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on NCT00541216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541216.